Clinical Trials Sponsored by Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National In

Total 3293 results

National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
International AIDS Vaccine Initiative

Withdrawn

Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults

HIV Infections
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals

HIV Infections | Hepatitis C

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Options for Second-Line Effective Combination Therapy (SELECT) (SELECT)

HIV-1 Infection

Peru, Kenya, Malawi, Brazil, South Africa, Zimbabwe, India, Thailand, Tanzania
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

HIV-1 and Hepatitis C Co-Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

HIV-1 Infection

United States, Peru, Puerto Rico, Brazil, Botswana, Kenya, South Africa, Thailand
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy

HIV Infections

Malawi, South Africa, India, Tanzania, Thailand
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Telephone Support to Improve Adherence to Anti-HIV Medications

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load

HIV Infections

United States, Haiti
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis

HIV-1 Infection

Kenya, Malawi, Uganda, South Africa, Zimbabwe, Botswana, India
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

HIV Infections

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People (FASTER)

HIV Infections

Peru, Brazil, South Africa
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); AbbVie

Completed

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

HIV Infection | Hepatitis C Infection

United States, Brazil
National Institute of Allergy and Infectious Diseases...
Allergan

Withdrawn

Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV Infections
National Institute of Allergy and Infectious Diseases...
Adult AIDS Clinical Trials Group

Completed

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Neurologic AIDS Research Consortium (NARC)

Completed

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

HIV Infections | Peripheral Nervous System Diseases

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Pfizer

Completed

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical...

Terminated

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

HIV Infections

United States, Peru
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Neurologic AIDS...

Terminated

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group; Acute Infection and Early Disease Research Program

Completed

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

HIV Infections

United States, American Samoa, Australia
Massachusetts General Hospital
National Institute of Allergy and Infectious Diseases (NIAID); AIDS Healthcare...

Completed

Test and Treat TB: A Proof of Concept Trial in South Africa (Siyasiza)

Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

HIV

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Protocol CAUSE-03 / CHEETAH (CHEETAH)

Asthma

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases...

Recruiting

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (LEADS)

Atopic Dermatitis

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis (VIBRANT)

Lupus Nephritis

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Linezolid Dosing Strategies in Drug-Resistant TB

Tuberculosis | Tuberculosis, Pulmonary | Tuberculosis, Multidrug-Resistant

Brazil, India, Kenya, Philippines, South Africa, Zimbabwe, Thailand, Haiti, Peru, Botswana
National Institute of Allergy and Infectious Diseases...

Recruiting

A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)

Dengue Fever

Brazil
National Institute of Allergy and Infectious Diseases...

Recruiting

Phase 2 Shigella Vaccine and Challenge

Immunisation | Shigella Infection

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

Monkeypox

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Completed

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Rabies | Rabies Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

Zika Virus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

COVID-19

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...

Suspended

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Ebola Virus Disease

United States
National Institute of Allergy and Infectious Diseases...

Completed

Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Gonorrhoea

United States

Clinical Trials Sponsored by Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National In

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations